 Rasa Kazlauskaite
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiposity | 8 | 2018 | 45 | 2.140 |
Why?
| | Intra-Abdominal Fat | 5 | 2015 | 42 | 1.790 |
Why?
| | Menopause | 6 | 2018 | 94 | 1.760 |
Why?
| | Women's Health | 9 | 2018 | 168 | 1.560 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2015 | 173 | 1.550 |
Why?
| | Obesity | 5 | 2018 | 262 | 1.460 |
Why?
| | Thrombosis | 2 | 2014 | 59 | 1.210 |
Why?
| | Obesity, Abdominal | 4 | 2015 | 19 | 1.190 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 120 | 1.130 |
Why?
| | Cardiovascular Diseases | 6 | 2016 | 271 | 1.100 |
Why?
| | Adrenal Gland Diseases | 2 | 2012 | 3 | 1.090 |
Why?
| | Diet Therapy | 1 | 2018 | 11 | 0.930 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 11 | 0.920 |
Why?
| | Abdominal Fat | 2 | 2015 | 10 | 0.890 |
Why?
| | African Americans | 7 | 2017 | 584 | 0.880 |
Why?
| | Behavior Therapy | 1 | 2018 | 69 | 0.870 |
Why?
| | Middle Aged | 26 | 2018 | 9041 | 0.860 |
Why?
| | Exercise Therapy | 1 | 2018 | 96 | 0.840 |
Why?
| | Hydrocortisone | 3 | 2012 | 44 | 0.830 |
Why?
| | Testosterone | 2 | 2014 | 34 | 0.830 |
Why?
| | Waist-Height Ratio | 1 | 2016 | 4 | 0.820 |
Why?
| | Metabolic Diseases | 1 | 2016 | 14 | 0.810 |
Why?
| | Ethnic Groups | 3 | 2015 | 119 | 0.780 |
Why?
| | Female | 31 | 2018 | 14313 | 0.740 |
Why?
| | Mass Screening | 1 | 2016 | 152 | 0.720 |
Why?
| | European Continental Ancestry Group | 6 | 2017 | 495 | 0.710 |
Why?
| | Risk Factors | 16 | 2016 | 2048 | 0.710 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2014 | 48 | 0.650 |
Why?
| | Humans | 34 | 2018 | 24291 | 0.640 |
Why?
| | Atherosclerosis | 2 | 2011 | 32 | 0.640 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2013 | 10 | 0.630 |
Why?
| | Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.620 |
Why?
| | Prevalence | 4 | 2016 | 449 | 0.600 |
Why?
| | Hemodynamics | 1 | 2012 | 89 | 0.600 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2009 | 10 | 0.590 |
Why?
| | Adult | 17 | 2016 | 7876 | 0.590 |
Why?
| | Liver Cirrhosis | 1 | 2012 | 55 | 0.580 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2009 | 3 | 0.580 |
Why?
| | Lipoproteins, HDL | 3 | 2014 | 28 | 0.570 |
Why?
| | Diastole | 1 | 2010 | 34 | 0.510 |
Why?
| | Vitamin D | 1 | 2010 | 17 | 0.510 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 7 | 0.510 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 74 | 0.510 |
Why?
| | Cardiomyopathies | 1 | 2010 | 31 | 0.500 |
Why?
| | Pituitary Diseases | 1 | 2008 | 3 | 0.470 |
Why?
| | Hypothalamic Diseases | 1 | 2008 | 6 | 0.470 |
Why?
| | Reproducibility of Results | 4 | 2014 | 699 | 0.460 |
Why?
| | Depression | 3 | 2018 | 401 | 0.420 |
Why?
| | United States | 8 | 2016 | 1838 | 0.400 |
Why?
| | Sensitivity and Specificity | 3 | 2014 | 551 | 0.390 |
Why?
| | Ketone Bodies | 1 | 2005 | 5 | 0.380 |
Why?
| | ROC Curve | 3 | 2009 | 102 | 0.360 |
Why?
| | Male | 12 | 2018 | 14066 | 0.350 |
Why?
| | Insulin | 2 | 2011 | 88 | 0.330 |
Why?
| | Cohort Studies | 5 | 2016 | 1431 | 0.330 |
Why?
| | Chicago | 5 | 2014 | 729 | 0.330 |
Why?
| | Hispanic Americans | 1 | 2005 | 149 | 0.330 |
Why?
| | Life Style | 2 | 2018 | 165 | 0.320 |
Why?
| | Atrial Appendage | 2 | 2014 | 31 | 0.320 |
Why?
| | Waist Circumference | 4 | 2016 | 28 | 0.310 |
Why?
| | Hypoglycemic Agents | 1 | 2003 | 63 | 0.300 |
Why?
| | Energy Metabolism | 2 | 2018 | 71 | 0.300 |
Why?
| | Postmenopause | 4 | 2015 | 61 | 0.300 |
Why?
| | Stroke Volume | 2 | 2014 | 43 | 0.290 |
Why?
| | Cosyntropin | 2 | 2012 | 3 | 0.270 |
Why?
| | Estradiol | 3 | 2017 | 45 | 0.270 |
Why?
| | Insulin Resistance | 4 | 2011 | 54 | 0.260 |
Why?
| | Cholesterol, HDL | 3 | 2011 | 27 | 0.260 |
Why?
| | Follow-Up Studies | 6 | 2016 | 1692 | 0.260 |
Why?
| | Longitudinal Studies | 6 | 2016 | 1080 | 0.250 |
Why?
| | Aged | 9 | 2015 | 8000 | 0.250 |
Why?
| | Blood Glucose | 4 | 2014 | 108 | 0.250 |
Why?
| | Body Mass Index | 4 | 2017 | 341 | 0.240 |
Why?
| | Exercise | 2 | 2018 | 283 | 0.240 |
Why?
| | Appetite | 1 | 2018 | 5 | 0.240 |
Why?
| | Weight Gain | 1 | 2018 | 57 | 0.220 |
Why?
| | Body Weight | 1 | 2018 | 142 | 0.220 |
Why?
| | Hypertension | 3 | 2014 | 193 | 0.220 |
Why?
| | Weight Loss | 1 | 2018 | 92 | 0.220 |
Why?
| | Hormones | 1 | 2017 | 12 | 0.220 |
Why?
| | Perimenopause | 1 | 2017 | 13 | 0.210 |
Why?
| | Menstrual Cycle | 1 | 2017 | 33 | 0.210 |
Why?
| | Retrospective Studies | 5 | 2014 | 2386 | 0.210 |
Why?
| | Prospective Studies | 4 | 2016 | 1372 | 0.210 |
Why?
| | Social Support | 1 | 2018 | 171 | 0.210 |
Why?
| | Beverages | 1 | 2016 | 14 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2009 | 683 | 0.200 |
Why?
| | Depressive Disorder | 1 | 2018 | 206 | 0.200 |
Why?
| | Climacteric | 1 | 2015 | 10 | 0.190 |
Why?
| | Child | 3 | 2009 | 1260 | 0.190 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 17 | 0.190 |
Why?
| | False Positive Reactions | 1 | 2015 | 36 | 0.190 |
Why?
| | Estrogens | 1 | 2015 | 36 | 0.180 |
Why?
| | Immunoassay | 1 | 2015 | 39 | 0.180 |
Why?
| | Carbonated Beverages | 1 | 2014 | 2 | 0.180 |
Why?
| | Research Report | 1 | 2014 | 5 | 0.180 |
Why?
| | Sweetening Agents | 1 | 2014 | 6 | 0.180 |
Why?
| | Waist-Hip Ratio | 1 | 2014 | 13 | 0.180 |
Why?
| | Meals | 1 | 2014 | 9 | 0.180 |
Why?
| | Birth Weight | 1 | 2015 | 41 | 0.180 |
Why?
| | Algorithms | 2 | 2009 | 372 | 0.180 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2015 | 35 | 0.180 |
Why?
| | Illinois | 2 | 2013 | 205 | 0.170 |
Why?
| | Oligomenorrhea | 1 | 2014 | 1 | 0.170 |
Why?
| | Hyperandrogenism | 1 | 2014 | 2 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 739 | 0.170 |
Why?
| | Population Surveillance | 1 | 2014 | 108 | 0.170 |
Why?
| | Employment | 1 | 2013 | 28 | 0.170 |
Why?
| | Personal Satisfaction | 1 | 2014 | 41 | 0.160 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 51 | 0.160 |
Why?
| | Body Image | 1 | 2014 | 36 | 0.160 |
Why?
| | Heart Valve Diseases | 1 | 2013 | 15 | 0.160 |
Why?
| | Time Factors | 3 | 2014 | 1581 | 0.160 |
Why?
| | Body Fat Distribution | 1 | 2012 | 11 | 0.150 |
Why?
| | Ultrasonography | 1 | 2013 | 154 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 189 | 0.150 |
Why?
| | Up-Regulation | 1 | 2012 | 184 | 0.140 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 319 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 522 | 0.130 |
Why?
| | Calcifediol | 1 | 2010 | 2 | 0.130 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 3 | 0.130 |
Why?
| | Breast Neoplasms | 2 | 2015 | 381 | 0.130 |
Why?
| | Infant | 2 | 2009 | 533 | 0.130 |
Why?
| | Metyrapone | 1 | 2009 | 1 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2010 | 39 | 0.130 |
Why?
| | Glucose Tolerance Test | 1 | 2009 | 11 | 0.130 |
Why?
| | Pericardium | 1 | 2010 | 24 | 0.130 |
Why?
| | Reference Standards | 1 | 2009 | 31 | 0.130 |
Why?
| | Particle Size | 1 | 2010 | 67 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2010 | 56 | 0.130 |
Why?
| | Antimetabolites | 1 | 2009 | 13 | 0.130 |
Why?
| | Child, Preschool | 2 | 2009 | 698 | 0.120 |
Why?
| | Prognosis | 1 | 2012 | 796 | 0.120 |
Why?
| | Hospitals, Public | 1 | 2009 | 30 | 0.120 |
Why?
| | Risk Assessment | 1 | 2012 | 628 | 0.120 |
Why?
| | Regression Analysis | 1 | 2010 | 288 | 0.120 |
Why?
| | Health Behavior | 1 | 2010 | 142 | 0.120 |
Why?
| | Diet | 1 | 2010 | 164 | 0.120 |
Why?
| | Fasting | 1 | 2008 | 21 | 0.120 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2008 | 20 | 0.110 |
Why?
| | Urban Population | 1 | 2009 | 131 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2008 | 57 | 0.110 |
Why?
| | Hypercalcemia | 1 | 2007 | 7 | 0.110 |
Why?
| | Burns | 1 | 2007 | 20 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1050 | 0.100 |
Why?
| | Asian Continental Ancestry Group | 2 | 2017 | 50 | 0.100 |
Why?
| | Blood Pressure | 3 | 2015 | 183 | 0.100 |
Why?
| | Motor Activity | 1 | 2010 | 358 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2014 | 4040 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 99 | 0.100 |
Why?
| | Incidence | 3 | 2015 | 639 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2007 | 162 | 0.090 |
Why?
| | Adolescent | 2 | 2009 | 2183 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2007 | 225 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 181 | 0.090 |
Why?
| | Lamin Type A | 1 | 2004 | 2 | 0.090 |
Why?
| | Lipodystrophy | 1 | 2004 | 2 | 0.090 |
Why?
| | Acyltransferases | 1 | 2004 | 4 | 0.090 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.090 |
Why?
| | Neuropsychological Tests | 1 | 2009 | 1080 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 86 | 0.080 |
Why?
| | Gluconeogenesis | 1 | 2003 | 4 | 0.080 |
Why?
| | Energy Intake | 2 | 2016 | 79 | 0.080 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2003 | 14 | 0.080 |
Why?
| | Odds Ratio | 2 | 2015 | 269 | 0.080 |
Why?
| | Hyperlipidemias | 1 | 2003 | 23 | 0.080 |
Why?
| | Young Adult | 1 | 2009 | 1650 | 0.080 |
Why?
| | Fatty Acids | 1 | 2003 | 42 | 0.080 |
Why?
| | Triglycerides | 2 | 2014 | 46 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2004 | 287 | 0.080 |
Why?
| | Age Factors | 1 | 2005 | 756 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 370 | 0.070 |
Why?
| | Cognition | 1 | 2009 | 824 | 0.070 |
Why?
| | Patient Selection | 1 | 2003 | 216 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2016 | 303 | 0.070 |
Why?
| | Liver | 1 | 2003 | 194 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 316 | 0.070 |
Why?
| | Hypertriglyceridemia | 2 | 2014 | 23 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2009 | 1033 | 0.060 |
Why?
| | Disease Progression | 1 | 2003 | 709 | 0.060 |
Why?
| | Pregnanediol | 1 | 2017 | 5 | 0.050 |
Why?
| | Estrone | 1 | 2017 | 7 | 0.050 |
Why?
| | Corpus Luteum | 1 | 2017 | 4 | 0.050 |
Why?
| | Luteinizing Hormone | 1 | 2017 | 8 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2017 | 18 | 0.050 |
Why?
| | Premenopause | 1 | 2017 | 20 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 15 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 17 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 50 | 0.050 |
Why?
| | E-Selectin | 1 | 2015 | 4 | 0.050 |
Why?
| | Androgens | 1 | 2014 | 7 | 0.040 |
Why?
| | Linear Models | 1 | 2014 | 247 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2015 | 338 | 0.040 |
Why?
| | Logistic Models | 1 | 2014 | 429 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2015 | 555 | 0.040 |
Why?
| | Myocardial Infarction | 1 | 2014 | 162 | 0.040 |
Why?
| | Tunica Intima | 1 | 2011 | 32 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2011 | 44 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2010 | 15 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 59 | 0.030 |
Why?
| | France | 1 | 2010 | 35 | 0.030 |
Why?
| | Vegetables | 1 | 2010 | 16 | 0.030 |
Why?
| | Fruit | 1 | 2010 | 20 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2010 | 39 | 0.030 |
Why?
| | Dietary Fats | 1 | 2010 | 45 | 0.030 |
Why?
| | Stroke | 1 | 2014 | 290 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2009 | 15 | 0.030 |
Why?
| | Biological Availability | 1 | 2009 | 24 | 0.030 |
Why?
| | Aging | 1 | 2018 | 1199 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 356 | 0.030 |
Why?
| | Albumins | 1 | 2007 | 32 | 0.030 |
Why?
| | Knowledge | 1 | 2007 | 17 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2007 | 41 | 0.030 |
Why?
| | Lipids | 1 | 2007 | 51 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2015 | 2995 | 0.020 |
Why?
| | Length of Stay | 1 | 2007 | 275 | 0.020 |
Why?
| | 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2004 | 2 | 0.020 |
Why?
| | Consanguinity | 1 | 2004 | 3 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2004 | 6 | 0.020 |
Why?
| | Pennsylvania | 1 | 2004 | 13 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2004 | 14 | 0.020 |
Why?
| | Hyperinsulinism | 1 | 2004 | 5 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2004 | 40 | 0.020 |
Why?
| | Exons | 1 | 2004 | 44 | 0.020 |
Why?
| | Homozygote | 1 | 2004 | 24 | 0.020 |
Why?
| | Haplotypes | 1 | 2004 | 60 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2004 | 36 | 0.020 |
Why?
| | Alleles | 1 | 2004 | 183 | 0.020 |
Why?
| | Phenotype | 1 | 2004 | 312 | 0.020 |
Why?
| | Calcium | 1 | 2007 | 466 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2004 | 384 | 0.020 |
Why?
|
|
Kazlauskaite's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|